Find here a listing of the latest industry news in genomics, genetics, precision medicine, and beyond. We will update and add to this page on a regular basis. This page is not a compilation of all relevant information but rather contains some key highlights that we consider to be of importance to share with the community.

Sign-Up for our newsletter and never miss out on the latest news and updates.

Check out our News Portal with real-time listing of news and articles in genomics, genetics, precision medicine, and beyond.

News for the month June 2026

Funding & IPO

GRAIL Completes $110 Million Equity Financing With Samsung Entities
**Clair Health Raises $11.6 Million to Develop Continuous Hormone Monitoring Wearable Clair Health’s $11.6 million funding highlights a major shift toward AI-powered, continuous, noninvasive hormone monitoring that could make women’s health more personalized and data-driven—provided the company’s machine learning models can reliably infer hormone changes from wearable sensor data.
**Element Biosciences Announces Upsized Series E (including $175 million from longstanding investor Samsung Electronics, and an undisclosed amount from other investors) to Accelerate Global Growth Across Ecosystem of Genomic, Multiomic, and Clinical Research Solutions
Big Pharma-backed SonoThera sounds off with $125M series B for bubble-based genetic delivery The capital pushes its lead Duchenne muscular dystrophy program and an autosomal dominant polycystic kidney disease candidate toward the clinic.
Triveni Bio Raises $65 Million Series C Financing to Expand Scope of First-in-Class Bispecific TRIV-573 Clinical Studies and Drive Next-Stage Company Growth
Ethyreal Bio Emerges from Stealth with $101 Million in Financing to Advance ETHY-001, a Potentially Best-in-Class Anti-TSHR Antibody for Thyroid Eye Disease and Graves’ Disease
Mammogen Secures Up to $30 Million Series A Financing to Advance RNA-Based Breast Cancer Detection Platform
**Anti-aging startup NewLimit raised $435 million in Series C funding on June 2, 2026, at a $3.1 billion valuation The biggest raise of the month, and not by a little. NewLimit — the longevity company backed by Coinbase’s Brian Armstrong — closed a $435 million Series C led by Founders Fund, Thrive Capital, and Greenoaks, with Kleiner Perkins, Eli Lilly Ventures, and others joining
City Therapeutics Announces $99.5 Million Series B Financing to Advance Next-Generation RNAi Therapeutics
Merck KGaA pledges $50M to build new cardio biotech with eye to later acquisition
Sanger scientists to receive major grants from the European Research Council
**Sangamo Therapeutics Files for Chapter 11 Bankruptcy – Enters Into Asset Sale Agreements with Lilly and Astellas
Contraline, a clinical-stage biopharmaceutical company developing novel male contraceptives, announced the closing of a $92.5 million Series B financing

Mergers & Acquisitions

**Merck KGaA throws down $11.3B for Bio-Techne in its biggest deal since 2015 Sigma-Aldrich buy

Precision Medicine

German Brain Disease Center to Sequence 25K Genomes A globally unparalleled data base aims to advance research into brain disorders
Abu Dhabi Biobank, BioTwin unite to advance AI in healthcare
The Department of Health – Abu Dhabi (DoH) has signed a Memorandum of Understanding (MoU) with Novartis Middle East to explore collaboration in genomics research, scientific capacity building, and advanced therapies.
Genomics Launches the Mystra AI Platform, Adopted by Industry Giants and Up-and-Coming Biotechs
Tempus Announces Research Collaboration with Angiosarcoma Awareness, Inc. to Uncover Insights on Rare Cancers
**WHO advances precision medicine as a global health priority The WHO adopted a resolution in May 2026 to integrate precision medicine — combining genomic, molecular, and clinical data for personalized care — into global health systems, with a focus on equity, ethics, and access in low- and middle-income countries.

AL / ML / DL / GenAI / LLM / ChatGPT/Agentic A

**Anthropic releases Claude Science, a product aimed at researchers, the pharma industry
**Insilico Medicine, SK Biopharmaceuticals strike AI drug discovery deal valued at $2.5 billion targeting neuroimmune therapies
With $15M discovery deal, Boehringer becomes latest Big Pharma to buy into Immunai’s AI platform
**Insilico Medicine And SK Biopharmaceuticals Achieved AI-powered Drug Discovery Collaboration Worth Up to 2.5 Billion for Neuroimmune Disorders
Microsoft, Mayo Clinic plan to build frontier AI model for healthcare
**After hospitals, patients get a turn to bring AI into the doctor’s office Developers pitch their patient apps as diligent note-takers to keep track of encounters across the health system
Nvidia Is Developing an AI Healthcare Model With Startup Abridge The chip giant is joining with the maker of AI note-taking technology to train a model tailored for clinical conversations

Everything Data: RWE/RWD, Clinico-Genomic Data, Knowledge Graph, EHR, Data Platforms

**The Invisible Infrastructure: Bio-IT World Panel Warns of a Slow-Motion Crisis in Biomedical Data Researchers are warning that cuts to publicly funded biomedical data infrastructure threaten the foundation of AI-driven drug discovery, innovation, and future healthcare unless these critical resources are protected.
Cell-type-specific proximity labeling of organ secretomes reveals energy balance-dependent proteomic remodeling The study maps a hidden communication network between organs

Miscellaneous

**First use of precision editing to study human embryo development reveals role of master gene Study sheds light on early development, but also sparks concerns
Natera Faces Class Action Lawsuit Alleging Misleading Genetic Testing Claims (GenomeWeb)
Colossal and the US Government Are Creating an Endangered Species ‘BioVault’ Colossal Bio, US Fish and Wildlife Service to Sequence, Archive Genomes of 2,300 Endangered Species
Natera’s Signatera™ Receives Regulatory Approval in Japan for Colorectal Cancer
AI Drug Discovery Reaches Clinical Proof at BIO 2026: China Beat the BIOSECURE Act to Science (BIO San Diego)
**US Immigration Policies Fuel Fear of Life Science Brain Drain, Survey Shows (GenomeWeb)
Regeneron’s Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG)
FDA Approves Oral Antiviral to Prevent COVID-19 After Exposure
How Eli Lilly Got Huge By Making Us Thin
Google unveils smartphone camera-based heart rate monitoring system
Apple’s Health app can now tell you if you’re in perimenopause
2026 Warren Alpert Foundation Prize Awarded for Gene-Editing Therapies

Publications

**Biological aging and generational shifts in early-onset cancer risk The study highlighted a generational aging shift:
People born in 1965–1974 showed a 23% higher “age gap” (biological age ahead of chronological age) compared to those born in 1950–1954. This pattern held in both the UK and US cohorts, and was steeper in women than men.
General-purpose large language models outperform specialized clinical AI tools on medical benchmarks
**Single-cell map of the healthy human immune system across the lifespan reveals unique infant immune signatures Using scRNA-seq and snATAC-seq across 167 healthy individuals from infancy to age 105, this study builds the most comprehensive single-cell immune atlas of the human lifespan to date — revealing how key populations like CD8⁺ T cells, MAIT cells, and γδ T cells are systematically remodeled with age. A standout finding is that infants and the oldest-old share distinct immune signatures that likely explain their common vulnerability to infection and poor vaccine responses, with implications for age-tailored therapeutic and immunization strategies.
**Mapping the neuronal building blocks of human language with language models Researchers discover single-cell brain activity that underlies human speech
Future Prospects for Omics Sciences: Expanding the Boundaries of Systems Biology This review organizes established and emerging omics into a structured framework, highlighting conceptual innovations such as adaptomics, resiliomics, chrono-adaptomics, and signalomics. It discusses technological advances, computational strategies, and potential applications for research and clinical practice.
SF3B1 phosphorylation is an evolutionarily conserved step in spliceosome activation carried out by the divergent, OTS964-insensitive kinase CRK9 in trypanosomes This antisense RNA was designated as a “Breakthrough Article” by Nucleic Acids Research
Multi-omics and artificial intelligence for precision drug discovery and potential clinical applications

News for the month May 2026

May highlighted the accelerating convergence of AI, precision medicine, genomics, and drug discovery.

Major investments continued to flow into AI-driven biology, led by Isomorphic Labs’ $2.1 billion raise, while Eli Lilly expanded aggressively into infectious disease through three acquisitions worth up to $3.8 billion and Roche strengthened its digital pathology portfolio with its planned acquisition of PathAI.

Artificial intelligence remained a dominant theme throughout the month. New partnerships (BMS taps Anthropic’s Claude; Incyte and Edison Scientific announce collaboration; AZ pens agentic AI licensing deal with Owkin; Elsevier introduces SciBite Chat), foundation models, and AI-powered platforms continued to move from experimentation toward practical deployment across research and healthcare. At the same time, growing attention was placed on interpretability, transparency, and trust as AI systems become increasingly involved in scientific and clinical decision-making.

Notable scientific publications included studies linking sleep duration to biological aging across multiple organ systems, single-cell analyses revealing how sex influences immune function, advances in pangenome annotation through KaryoScope, and large-scale research showing how rare variants, polygenic background, and environmental factors interact to shape complex traits. Lastly, notable scientific advances also included encouraging clinical data from Verve Therapeutics’ VERVE-102, demonstrating the potential of in vivo base editing to permanently lower LDL cholesterol through a one-time treatment, highlighting the growing promise of gene editing as a preventative approach to common chronic diseases.

Together, these developments reinforce a clear trend: AI is becoming an integral part of the infrastructure that powers modern biology, drug discovery, and precision medicine.

Funding & IPO

Latus Bio Announces $97 Million Series A Financing to Expand the Reach of Gene Therapy to Larger Populations
XCaliber Health scores $6.5M for workflow platform XCaliber Health, a company offering an agentic AI platform aimed at reducing administrative burden in healthcare, has raised $6.5 million in seed funding to scale its platform nationwide.
DeepMind spinout Isomorphic Labs raises $2.1 billion to design drugs with AI
Dandelion Health raises $14M for precision medicine platform
**Iterative Health banks $77m to level up AI-driven clinical research tech The Google Ventures-backed health technology company will now expand its platform into burgeoning therapeutic areas like cardiology and obesity.

Mergers & Acquisitions

**Lilly announces three acquisitions to build infectious disease portfolio Eli Lilly is acquiring Curevo, LimmaTech Biologics, and Vaccine Company to build a diversified infectious disease portfolio spanning shingles, antimicrobial-resistant bacterial infections, and Epstein-Barr virus (EBV), with a combined potential deal value of approximately $3.8 billion.
Roche to acquire digital pathology firm PathAI for up to $1.05B Roche plans to offer PathAI’s tools as part of an effort to improve cancer diagnosis and tailored treatment.
InSphero AG Acquires PhenoVista Biosciences, Inc. to Expand Advanced 3D, Cell-based Assay Capabilities

Partnerships

Helio Genomics Announces Strategic Commercial Partnership with Syneos Health® to Accelerate Nationwide Adoption of HelioLiver™, A Breakthrough AI-Powered Blood Test for Early Liver Cancer Detection

Precision Medicine

Tempus Launches the PRECISION Challenge, a National Program Opening Its Foundation Model Work to the Broader Research Community
**World Health Assembly endorses resolution on precision medicine
Mayo Clinic and Stanford researchers develop first blood test to map tumor “neighborhoods,” improving prediction of therapy response
Personalis Secures Fourth Medicare Coverage Decision for NeXT Personal®, Expanding Breast Cancer Coverage to Pre-Surgical Treatment Monitoring
FDA Approves Genentech’s Tecentriq for Adjuvant Muscle-Invasive Bladder Cancer With ctDNA-Guided Treatment
Precision Medicine’s Next Hurdle Isn’t Science — It’s Execution A new UPMC report found that while most health systems now offer precision medicine programs, many still face challenges scaling them due to reimbursement, data integration and patient engagement issues. Health system leaders say the field’s future depends on embedding genomics into routine care, as well as proving its clinical and financial value.

Diagnostics / Genomic / Genetic Testing / CDx

GRAIL Presents PATHFINDER 2 Results of More Than 35,000 Participants Showing the Galleri^® Test Substantially Increased Cancer Detection With Robust Performance and Favorable Safety (ASCO)
Datar Cancer Genetics Receives FDA Clearance for CellDx-Tissue, a Comprehensive Genomic Profiling Assay for Solid Tumors Using DNA + RNA
U.S. Food and Drug Administration Approves FoundationOne®CDx as a Companion Diagnostic for TEPMETKO® (tepotinib) to Identify Patients with MET Exon 14 Skipping Alterations in Non-Small Cell Lung Cancer
Scientists play catch-up to startling Ebola outbreak Testing, sequencing, and clinical trial efforts spring to life as Bundibugyo virus spreads
FDA Approves New Guardant360 Liquid CDx, the Largest FDA-Approved Liquid Biopsy Panel with a 100x Expanded Footprint

(Omics) Data Platform / Sequencing / Analysis / Instruments

Spatial Omics

10x Genomics Predicts Cannibalization of Spatial Instrument Sales with Atera The single cell and spatial biology firm reported Q1 revenue of $150.8 million, compared to $154.9 million a year ago, a decrease of 3 percent year over year.

Gene Editing

Eli Lilly PCSK9 Gene Editing Treatment Shown to Safely Reduce LDL Cholesterol in Early Trial

Longevity, Health Span, and Life Expectancy

Insilico Medicine and Human Longevity Announce Collaboration to Co-Develop Industry-First AI Foundation Model for Longevity Science

Miscellaneous

Moderna and Merck Halt Key mRNA Skin Cancer Trial: What Investors Should Know
Genedata Introduces AI-Native CMC Platform to Accelerate Drug Development and Manufacturing
The Fight for Research Integrity Needs You Elisabeth Bik has built a career exposing problematic papers. Now she is asking analytical scientists to apply the same scrutiny to their own fields.
**10x Genomics settles suit with rival and targets DNA sequencing startup
**Element Biosciences Responds to 10x Genomics Patent Infringement Complaint
**ARUP Laboratories Launches National Infectious Disease Test Positivity Trends Dashboard
36 New Products at Bio-IT World 2026
**BEVIMI Launches Uno Protect, a Patent-Pending Liquid Brain Health Formulation with Ten Clinically Studied Actives
Healthcare bankruptcies up 33% in Q1 2026: report However, the report (PDF) notes such filings are in line with the seven-year quarterly average.
**FDA withdrew studies finding Covid and shingles vaccines were safe The Food and Drug Administration blocked the publication of several studies supporting the safety of vaccines against Covid and shingles in recent months
Supreme Court temporarily restores ability to receive abortion drug mifepristone by mail

AL / ML / DL / GenAI / LLM / ChatGPT/Agentic AI

A Working Map of Foundation Models in Healthcare and Life Sciences Provides a practical framework for understanding where AI foundation models are creating real value across biology, chemistry, and clinical medicine, helping researchers, biotech companies, and investors navigate an increasingly crowded and confusing AI landscape. More importantly, it highlights that the future challenge is no longer just building more powerful models, but ensuring they are interpretable, trustworthy, and safe enough to support high-stakes scientific and clinical decisions.
BMS taps Anthropic’s Claude for enterprise-wide AI adoption to speed R&D, global workflows
Incyte and Edison Scientific Announce Strategic Collaboration to Employ the Kosmos AI Platform for Research and Development
AstraZeneca pens agentic AI licensing deal with Owkin
**Google’s $9.99-per-month AI health coach launches May 19
**Elsevier Introduces SciBite Chat, a transformative AI-Powered Semantic Search Tool for Life Sciences R&D (Bio-IT 2026)
OpenAI wants to ‘have their cake and eat it too’ with health AI policy recommendations The AI company’s proposals sound responsible but are self-interested, experts say
Hims & Hers debuts its first AI care agent to interpret biomarker lab results

Publications

Sleep chart of biological ageing clocks in middle and late life This study is important because it provides some of the strongest evidence to date that both too little (<6 hours) and too much (>8 hours) sleep are associated with accelerated biological aging across multiple organs and increased risks of diseases such as depression, diabetes, cardiovascular disease, and premature death, with the healthiest aging profiles occurring at roughly 6.5–7.8 hours of sleep per night. For longevity research, it moves the discussion beyond simple sleep recommendations by linking sleep duration directly to multi-omics and organ-specific aging clocks, suggesting that sleep may be a modifiable factor influencing biological age itself.
**The impact of sex on the immune system explored at the single-cell level
KaryoScope: rapid, alignment-free sequence annotation for the pangenome era This paper introduces KaryoScope, a fast, alignment-free genome annotation tool designed for the new “pangenome era,” where researchers are generating huge numbers of complete human genomes faster than traditional annotation methods can handle. It can rapidly identify and map difficult, highly variable genomic regions — such as centromeres and subtelomeres — revealing previously hidden structural variations linked to diseases like facioscapulohumeral muscular dystrophy and chromosomal rearrangements important for human genetics and clinical research.
**In Vivo Base Editing of PCSK9 with VERVE-102 for Hypercholesterolemia
** Boy’s brain tumor tied to gene therapy Researchers report first cancer caused by virus widely used to deliver genes, but say risk is low
**The association of time-restricted eating and indices of organ-specific aging in relation to metabolic health and obesity
Combinatorial effects of gene dosage, polygenic background and environment on complex traits Study shows, in more than 1.4 million people, how rare genetic variants (CNVs), common genetic risk factors, and environmental influences combine to shape complex traits like height and body weight, revealing that while many effects are additive, important gene-specific interactions and biological buffering mechanisms also exist.

News for the month April 2026

April saw strong momentum across AI, precision medicine, and life sciences, with the convergence of intelligent systems, advanced data platforms, and next-generation diagnostics becoming more evident. In AI, activity is accelerating—from OpenAI outlining its healthcare ambitions and launching GPT-Rosalind, to broader adoption of agentic AI across enterprise and clinical settings. At the same time, increased regulatory scrutiny highlights the need for safe deployment. New research also reinforces AI’s growing role in drug discovery, particularly in target identification.

In parallel, genomics and data-driven medicine continue to advance. Efforts like Tempus collaborating with Predicta Biosciences are expanding access to ultrasensitive sequencing, while Tempus’ partnership with Gilead underscores the importance of real-world data in oncology R&D. Across the ecosystem, new platforms and datasets are enabling more precise, personalized care.

Meanwhile, the broader landscape is evolving alongside these innovations. A collaboration between Paradigm Health and the U.S. Food and Drug Administration could modernize clinical trial review and accelerate approvals. The passing of J. Craig Venter also marks a significant moment for the genomics field. Together, these trends highlight a future driven by the integration of AI, biology, and data.

Funding / IPO

(Omics) Data Platform / Sequencing / Analysis / Instruments

Precision Medicine

The Lab Catches Up to the Clinic: How Functional Precision Oncology Goes Beyond Genomics
**Paradigm Health Announces Collaboration with the FDA to Transform Regulatory Review of Clinical Trial Data The collaboration between Paradigm Health and the U.S. Food and Drug Administration could modernize how clinical trial data is reviewed, potentially speeding up approvals for new drugs and therapies. By applying advanced data tools or AI to regulatory workflows, it may reduce bottlenecks, improve consistency, and bring treatments to patients faster.

Diagnostics / Genomic / Genetic Testing / CDx

MyGevity Announces Nationwide Launch of Integrated Health Data Platform
Diagnostics investments and disease burden Regulatory and payment policies could facilitate investment and innovation in diagnostics
**Tempus and Predicta Biosciences Announce Collaboration to Expand Life Sciences Access to Ultrasensitive Whole-Genome Sequencing Assay for Hematologic Malignancies and MRD Monitoring

AL / ML / DL / GenAI / LLM / ChatGPT/Agentic AI

**OpenAI’s head of health lays out the AI giant’s healthcare ambitions
**Utah medical board calls for immediate suspension of state’s AI doctor experiment
Merck and Google Cloud Partner to Accelerate Agentic AI Enterprise TransformationLongevity, Health Span, and Life Expectancy
Elephas Biosciences and Mithrl Pair Real-Time Tumor Profiling with Agentic AI to Unlock New Immunotherapy Response Insights
Catalyst Precision Health Launches the First Longevity Service for Men to Combine In-Home Lab Testing, Physician House Calls, and Continuous Personalized Care
**OpenAI launches AI model GPT-Rosalind for life sciences research The model aims to accelerate early-stage scientific discovery by helping researchers analyze data, generate hypotheses, and access scientific tools, and is available as a research preview through select OpenAI platforms.

Everything Data: RWE/RWD, Clinico-Genomic Data, Knowledge Graph, EHR, Data Platforms

Longevity, Health Span, and Life Expectancy

GB HealthWatch Launches AI-Ready Genetic Reports for the GB Longevity100 Suite
Longevity Science Is Overhyped. But This Research Really Could Change Humanity – A NY Times article – A new therapy has the potential to cure hundreds of diseases — and even reverse aging.

Miscellaneous

Publications

Genetic predictors of GLP1 receptor agonist weight loss and side effects
**Target identification and assessment in the era of AI Comprehensive review emphasizes key considerations in target selection, summarizes breakthroughs in the application of AI-driven approaches for therapeutic target exploration, and highlights clinical-stage successes in which AI played a pivotal role in target identification.
Targeted long-read RNA sequencing for rare disease diagnosis and variant interpretation Researchers from Children’s Hospital of Philadelphia (CHOP) developed a new RNA sequencing strategy that can reveal how genetic variants disrupt gene function and improve the diagnosis of rare diseases. The study team demonstrated that this platform could reveal disease-causing genetic variants and provide molecular diagnoses for previously undiagnosed patients, including five individuals whose conditions had remained unresolved after standard testing.
Sequence Display enables large-scale sequence–activity datasets for rapid protein evolution Sequence Display can generate more than 10 million data points in a single experiment. These data points are then fed into protein language AI models, which use them to predict which changes to a protein’s amino acids will create the desired change for the protein’s activity or function.
The circadian gene Dec2 promotes pancreatic cancer progression and dormancy through immune evasion Genetic discovery may explain why pancreatic cancer is so difficult to treat

News for the month March 2026

Funding / IPO

Translucent Announces $27M Series A to Tackle Healthcare’s Existential Financial Crisis

AL / ML / DL / GenAI / LLM / ChatGPT/Agentic AI

**Microsoft unveils Copilot Health as an AI health companion for consumers Copilot Health is an AI assistant for consumers that can review medical records, help them prepare for doctor appointments and offer personalized insights based on their health data
**AWS launches a new AI agent platform specifically for healthcare
Quest Diagnostics launches Google-powered AI chatbot to help patients understand lab results
HHS bans Claude AI tool as Trump seeks full government blacklisting of Anthropic

Miscellaneous

**Confidential health records from UK BioBank project exposed online The UK Biobank holds the medical records of 500,000 British volunteers, and is one of the world’s most comprehensive stores of health information and is credited with driving breakthroughs in cancer, dementia and diabetes research. It turns out confidential health data has been exposed online on dozens of occasions, a Guardian investigation can reveal, raising questions about the safeguarding of patient records by one of the UK’s flagship medical research projects.
**White House lifts hold on NIH research spending

Publications

AI with agency: a vision for adaptive, efficient, and ethical healthcare

News for the month February 2026

Funding / IPO

Mergers & Acquisitions

(Omics) Data Platform / Sequencing / Analysis / Instruments (AGBT 2026)

Diagnostics / Genomic / Genetic Testing / CDx

CareDx Announces Clinical Validation Results for AlloHeme™, the First AI‑Powered NGS Surveillance Solution for AML and MDS Post‑Cell Therapy

Precision Medicine

AL / ML / DL / GenAI / LLM / ChatGPT/Agentic AI

Miscellaneous

Publications

Multi-System Genetic Architecture of Hypermobile Ehlers–Danlos Syndrome: Integrating Machine Learning with Subject-Level Genomic Analysis
From correlation to causation: cell-type-specific gene regulatory networks in Alzheimer’s disease Causal gene mapping identifies key drivers of Alzheimer’s disease progression
Causal parametric language mapping with electrical stimulation during awake neurosurgery Study refines the limits of brain mapping

News for the month January 2026

Funding / IPO

**OpenEvidence clinches $250M series D as AI platform sees explosive growth with doctors
2025 year-end digital health funding overview: A tale of two markets A Rock Health report
Xella Health Raises $3.7 Million Pre-Seed to Launch Women’s Precision Health Platform
Carna Health Secures $8 Million to Expand Access to Scalable Chronic Kidney Disease Screening Solutions Globally Funding to accelerate innovation and growth following strategic partnership with Siemens Healthineers
RISA Labs Closes $11.1M Series A to Scale AI Operating System for Oncology Nationwide
Flywheel Raises $27.5 Million And Expands Clinical Trial And Medical Device Offerings
Protege Raises $30M Led by a16z to Unlock Access to Data for AI Development The company provides licensed, curated access to real-world and proprietary datasets across domains such as media, audio, and healthcare, supporting AI training and evaluation for major global AI companies.
bit.bio secures $50 million Series C to scale human cell programming technology

Mergers & Acquisitions

JPM26
**OpenAI acquires health-care technology startup Torch for $60 million
Hippocratic AI acquires Grove AI, taps life sciences leaders to focus on biopharma, medtech
**bioMérieux Acquires Accellix to Elevate Pharmaceutical Quality Control and Accelerate Advanced Therapies This strategic transaction, bioMérieux strengthens its Pharmaceutical Quality Control activity and invests in innovative solutions that will support the growing advanced therapy market and improve patient outcomes worldwide

Precision Medicine

**Genomics pioneer J. Craig Venter launches Diploid Genomics, Inc. (DGI), ushering in a new era in human genomics

(Omics) Data Platform / Sequencing / Analysis / Instruments

BioTuring and 10x Genomics Announce Strategic Collaboration to Streamline Single Cell and Spatial Data Analysis

Diagnostics / Genomic / Genetic Testing / CDx

**10x Genomics to Advance REsearch in Diagnostics Applications of Tumor Single Cell Profiling 10x announced clinical collaborations with two Boston-based institutions, Brigham & Women’s Hospital and Dana-Farber Cancer Institute, as well as the New York-based Cancer Research Institute. The company also committed to building its own CLIA-certified laboratory within about a year, with the goal of enabling clinical deployment of diagnostics that will come up with these kinds of collaborations.